AP
APUS.US Apimeds Pharmaceuticals US, Inc.
- Market cap
- USD 3.37M
- P/E
- -
- P/B
- 0.03x
- ROE
- -103.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is APUS.US undervalued?
Graham numberThe Graham number of Apimeds Pharmaceuticals US, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Apimeds Pharmaceuticals US, Inc. fundamental analysis
No fundamental analysis for Apimeds Pharmaceuticals US, Inc. yet.
Apimeds Pharmaceuticals US, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Apimeds Pharmaceuticals US, Inc.
Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company was incorporated in 2020 and is based in Matawan, New Jersey. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Inscobee., Inc.
Full company profileApimeds Pharmaceuticals US, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Apimeds Pharmaceuticals US, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | - | - | - | - | -5.71K | - |
| Operating Income | -1.02M | -640K | -747K | -1.28M | -11.9M | -20.7M |
| EBITDA | -1.02M | -640K | -740K | -1.27M | -5.71M | -102M |
| Net Income | -1.03M | -669K | -778K | -1.39M | -6.00M | -110M |
| EPS | -8.08 | -5.27 | -6.13 | -11 | -5.51 | -68 |
| Balance Sheet | ||||||
| Total Assets | 172K | 6.17K | 422K | 13.1K | 164M | 128M |
| Total Liabilities | 411K | 720K | 390K | 1.37M | 10.8M | 21.2M |
| Shareholders' Equity | -238K | -714K | 31.9K | -1.36M | 153M | 106M |
| Cash & Short-term Investments | 171K | 6.17K | 410K | 3.46K | 3.64M | 278K |
| Total Debt | 400K | 660K | 267K | 597K | 7.76M | 14.6M |
| Cash Flow | ||||||
| Operating Cash Flow | -823K | -448K | -628K | -734K | -8.93M | -16.6M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 57.3K | 18.8K |
| Free Cash Flow | -823K | -448K | -628K | -734K | -8.98M | -16.7M |
| Ratios | ||||||
| ROE | - | - | -2,440.1% | - | -3.9% | -103.8% |
| ROA | -596.1% | -10,835.6% | -184.3% | -10,645.6% | -3.7% | -86.6% |
| Debt to Equity | - | - | 8.37x | - | 0.05x | 0.14x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Apimeds Pharmaceuticals US, Inc. dividends
Apimeds Pharmaceuticals US, Inc. has not paid dividends in the last 5 fiscal years.
Last stock split: 1:10 on Jul 24, 2026.
Who owns Apimeds Pharmaceuticals US, Inc.
- Insiders 58.71%
- Institutions 2.83%
- Public & others 38.46%
- Shares outstanding 1.51M
- Free float 2.05M
Apimeds Pharmaceuticals US, Inc. company profile
- Company name
- Apimeds Pharmaceuticals US, Inc.
- Ticker
- APUS.US
- Exchange
- USA Stocks
- Listed since
- May 9, 2025
- Sector
- Healthcare
- Industry
- Capital Markets
- Employees
- 2
- Fiscal year end
- December
- Address
- 100 Matawan Rd, Matawan, NJ, United States, 07747
- Phone
- 848 201 5010
- Website
- mindwavedao.com
About Apimeds Pharmaceuticals US, Inc.
Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company was incorporated in 2020 and is based in Matawan, New Jersey. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Inscobee., Inc.
Apimeds Pharmaceuticals US, Inc. management
6- Mr. Erik C. EmersonPresident · born 1971
- Dr. Vinod MenonFounder & Co-CEO · born 1978
- Mr. Sungjoon ChaeCo-CEO & Director · born 1981
- Mr. Eric Michael Sherb CPAChief Financial Officer · born 1987
- Captain Sandeep Singh YadavChief Operating Officer
- Mr. Amardeep SinghChief Technology Officer